Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: Results from a phase 1 dose escalation and expansion study Meeting Abstract
| Authors: | Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W. B.; Erba, H. P.; Mannis, G. N.; Pollyea, D. A.; Stein, A. S.; Uy, G. L.; Watts, J. M.; Fathi, A. T.; Kantarjian, H. M.; Tallman, M. S.; Choe, S.; Dai, D.; Fan, B.; Wang, H.; Zhang, V.; Yen, K. E.; Kapsalis, S. M.; Hickman, D.; Liu, H.; Agresta, S. V.; Wu, B.; Attar, E. C.; Stone, R. M. |
| Abstract Title: | Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: Results from a phase 1 dose escalation and expansion study |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837601270 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-110595 |
| Notes: | Meeting Abstract: 561 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work